Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.AstraZeneca reported strong Q3 sales and raised its 2024 outlook, while avoiding questions about China and announcing plans to invest $2 billion in the U.S. market. Bayer's earnings were described as "not pretty" by CEO Bill Anderson, leading to a decline in stock value. Roche signed a potential $1.8 billion deal with Flare for cancer treatment, while 23andMe cut its workforce by 40% and ceased drug discovery work. Johns Hopkins University is partnering with a design team to prepare undergraduates for success in the biotech industry. Other news includes updates on companies like NKarta, Intellia, and Cassava, as well as FDA approvals and developments in the biopharma industry.